Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» zuranolone
zuranolone
A new $16,000 postpartum depression drug is here. How will insurers handle it?
Medical Marketing and Media
Wed, 03/13/24 - 11:11 am
zuranolone
postpartum depression
SAGE Therapeutics
Sage lays off 40%, shakes up C-suite to squeeze a profit out of partially rejected zuranolone
Fierce Biotech
Thu, 08/31/23 - 11:54 am
SAGE Therapeutics
layoffs
Biogen
major depressive disorcer
zuranolone
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
Mon, 08/14/23 - 11:23 am
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
FDA Approves Biogen, Sage’s Zurzuvae as First Pill for Postpartum Depression
BioSpace
Sun, 08/6/23 - 09:39 pm
Biogen
SAGE Therapeutics
FDA
Zurzuvae
postpartum depression
major depressive disorder
zuranolone
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
BioSpace
Mon, 07/31/23 - 10:05 am
FDA
graft vs host disease
head and neck cancer
postpartum depression
major depressive disorder
Mesoblast
remestemcel-L
Biogen
SAGE Therapeutics
zuranolone
Galera Therapeutics
avasopasem manganese
Go or no go? Biogen and Astellas head towards key PDUFAs
EP Vantage
Sat, 07/29/23 - 10:45 pm
FDA
Astellas
Zimura
Biogen
SAGE Therapeutics
zuranolone
major depressive disorder
postpartum depression
geographic atrophy
Sage Stock Drops Despite Promising Phase III Depression Data
BioSpace
Thu, 07/27/23 - 11:30 am
SAGE Therapeutics
zuranolone
Biogen
depression
9 Highly Anticipated FDA Decisions in Second Half of 2023
BioSpace
Fri, 06/30/23 - 11:52 am
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
SAGE Therapeutics
zuranolone
postpartum depression
major depressive disorder
Roche
Tecentriq
non-small cell lung cancer
CRISPR Therapeutics
Bluebird Bio
lovo-cel
exa-cel
BrainStorm Cell Therapeutics
NurOwn
5 FDA decisions to watch in the third quarter
BioPharma Dive
Mon, 06/26/23 - 10:04 am
FDA
SAGE Therapeutics
Biogen
zuranolone
Eisai
Leqembi
Sanofi
AstraZeneca
nirsevimab
Iveric Bio
Zimura
Alnylam
Onpattro
FDA says no adcomm planned for Biogen, Sage's depression drug
Seeking Alpha
Wed, 03/8/23 - 09:47 pm
Biogen
SAGE Therapeutics
FDA
zuranolone
major depressive disorder
postpartum depression
Biogen, Sage Get FDA Priority Review of Zuranolone
Marketwatch
Mon, 02/6/23 - 10:47 am
Biogen
SAGE Therapeutics
FDA
zuranolone
priority review
postpartum depression
major depressive disorder
Sage, Biogen post fresh phase 3 depression data as FDA filing nears completion
Fierce Biotech
Mon, 10/17/22 - 10:39 am
SAGE Therapeutics
Biogen
zuranolone
postpartum depression
clinical trials
Ahead of FDA filing, Sage and Biogen tout more data in hopes of alleviating durability concerns
Endpoints
Mon, 09/19/22 - 09:53 pm
SAGE Therapeutics
Biogen
major depressive disorder
zuranolone
Sage, Biogen drug meets goal in postpartum depression study
BioPharma Dive
Wed, 06/1/22 - 07:32 pm
SAGE Therapeutics
Biogen
FDA
zuranolone
postpartum depression
Sage, Biogen get rolling on FDA submission for depression med
Fierce Biotech
Mon, 05/2/22 - 11:52 am
SAGE Therapeutics
Biogen
zuranolone
FDA
major depressive disorder
Sage claims new data show depression drug works, but doubts remain
Biopharma Dive
Wed, 02/16/22 - 11:05 pm
SAGE Therapeutics
Biogen
depression
clinical trials
zuranolone
Where Will Biogen Be in 5 Years?
Motley Fool
Sun, 01/16/22 - 03:56 am
Biogen
Aduhelm
zuranolone
BIIB115
lecanemab
Sage changes primary endpoint in key study months after analysts fret about depression drug's durability
Endpoints
Wed, 11/3/21 - 10:41 am
SAGE Therapeutics
clinical trials
zuranolone
depression
endpoints
SSRIs
Biogen, Sage plot 2022 filing for zuranolone approval, furthering turnaround of depression drug
Fierce Biotech
Tue, 10/19/21 - 11:54 am
Biogen
SAGE Therapeutics
zuranolone
FDA
clinical depression
Biogen and Sage Present Positive Data for Breakthrough Depression Therapy
BioSpace
Mon, 10/4/21 - 10:55 pm
Biogen
SAGE Therapeutics
major depressive disorder
postpartum depression
clinical trials
zuranolone
Pages
1
2
next ›
last »